On November 14, 2019, after the review of the Shanghai Pudong New Area Science and Technology and Economic Commission, Luoqi Biology performed well in terms of enterprise operation, R&D investment, intellectual property, talent introduction and venture capital acquisition in the previous year, and won the special fund for key technology entrepreneurship enterprises in Pudong New Area science and technology development.

In October 2019, the latest research result of Shanghai Luoqi Biotechnology Co., Ltd., "Blocking the PD-1-PD-L1 axis by a novel PD-1specific Nanobody expressed in year as a potential thermal forever", was published in the journal of Biological and Biophysical Research Communications under ELSEVIER.

From September 28 to October 2, 2019, the 29th ERS (European Respiratory Society Annual Conference) was held in Madrid, Spain. More than 20000 colleagues from all over the world participated in the event. This ERS meeting covered the key topics of respiratory medicine in 14 scientific fields, including tuberculosis, lung cancer, chronic and acute respiratory failure, sleep disordered breathing, interstitial lung disease, pneumonia, cystic fibrosis, COPD and asthma.

On July 26, the 2019 Mid-Year Work Summary Meeting of Luoqi Biology was held in the Phase III Exhibition Center of Shanghai International Medical Park. All staff of the company attended the meeting, which was presided over by Zhu Min, assistant general manager.

On April 11, 2019, Shanghai Luoqi Bio-pharmaceutical Technology Co., Ltd. won the bid for the 2019 "Science and Technology Innovation Action Plan" in the field of biomedicine science and technology support project in Shanghai.

On March 1, 2019, Shanghai Luoqi Bio-pharmaceutical Technology Co., Ltd. and Zhejiang Terex Pharmaceutical Co., Ltd. signed a global strategic cooperation agreement, announcing that the two sides will carry out cooperation in various aspects in the field of tumor immunotherapy and nano-antibody drugs, with strong cooperation, complementary advantages and win-win cooperation. Dr. Wan Yakun, chairman of Rocky Biology, and Dr. Wu Youling, chief executive officer and chairman of Trisys Pharmaceutical attended the ceremony and signed. Xiong Quanlong, deputy director of the Standing Committee of Huzhou Municipal People's Congress and secretary of the Party Committee of the Development Zone, attended the ceremony and delivered an important speech.

On October 30, Luoqi Biology was invited to participate in the "Opening Ceremony of the 8th China Innovation and Entrepreneurship Competition (Shanghai) and 2019 Entrepreneurship in Shanghai International Innovation and Entrepreneurship Competition". At the ceremony, relevant leaders presented awards to the winners of the 2018 "Entrepreneurship in Shanghai" International Innovation and Entrepreneurship Competition.

From October 16, 2017 to October 16, 2018, the first anniversary of the founding of Rocky Biology! We are a group of young partners who are deeply engaged in the field of antibody drugs. This year, we have been moving forward, and this year, we have gained a lot!